HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- methyl- 4- (N- propyl- N- cycloproanemethylamino)- 5- chloro- 6- (2,4,6- trichloranilino)pyrimidine

Also Known As:

NBI 27914; NBI27914

Networked: 12 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine: 12
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine: 12

Experts

1.	Neugebauer, Volker: 3 articles (04/2008 - 06/2007)
2.	Amano, Taiju: 2 articles (01/2020 - 10/2019)
3.	Asaoka, Yuta: 2 articles (01/2020 - 10/2019)
4.	Hara, Ryuto: 2 articles (01/2020 - 10/2019)
5.	Minami, Masabumi: 2 articles (01/2020 - 10/2019)
6.	Nomura, Hiroshi: 2 articles (01/2020 - 10/2019)
7.	Takahashi, Daiki: 2 articles (01/2020 - 10/2019)
8.	Fu, Yu: 2 articles (04/2008 - 06/2007)
9.	Ji, Guangchen: 2 articles (06/2007 - 06/2007)
10.	Al-Madol, Mohammed: 1 article (06/2022)

Related Diseases

1.	Pain (Aches) 04/09/2008 - "NBI27914 inhibited arthritis pain-related behaviors (audible and ultrasonic vocalizations and hindlimb withdrawal reflexes). " 06/05/2007 - "Systemic or intraamygdalar (into the CeA) administration of NBI27914, but not vehicle, inhibited anxiety-like behavior and nocifensive pain responses, nearly reversing the arthritis pain-related changes. " 06/15/2022 - "Intracerebroventricular, but systemically inactive, doses of CRF elicited potent, dose-dependent antinociceptive effects in inflammatory pain which were significantly antagonized by i.c.v. CRF-R1-selective antagonist NBI 27914 (by approximately 60%) but less by CRF-R2-selective antagonist K41498 (by only 20%). " 09/01/2010 - "Results from the antagonist studies showed that CP-154,526 and NBI 27914 either fully or partially reversed the referred ulcer pain with minimal effective doses (MED) equal to 3 and 10 mg/kg, respectively. "
2.	Ulcer 09/01/2010 - "Results from the antagonist studies showed that CP-154,526 and NBI 27914 either fully or partially reversed the referred ulcer pain with minimal effective doses (MED) equal to 3 and 10 mg/kg, respectively. "
3.	Hypersensitivity (Allergy) 09/01/2010 - "For these studies, animals were dosed with CP-154,526 (3, 10, 30 mg/kg) and NBI 27914 (1-30 mg/kg) 1 h prior to the assessment of tactile, thermal or mechanical hypersensitivity, respectively. " 09/01/2010 - "Similarly, both NBI 27914 and CP-154,526 reversed the thermal and mechanical hypersensitivity elicited by carrageenan and FCA with MEDs </= 5 and 10 mg/kg, respectively. "
4.	Arthritis (Polyarthritis) 04/09/2008 - "NBI27914 inhibited arthritis pain-related behaviors (audible and ultrasonic vocalizations and hindlimb withdrawal reflexes). " 06/05/2007 - "Systemic or intraamygdalar (into the CeA) administration of NBI27914, but not vehicle, inhibited anxiety-like behavior and nocifensive pain responses, nearly reversing the arthritis pain-related changes. " 06/01/2007 - "A selective CRF1 receptor antagonist (NBI27914; 1-100 microM, concentration in microdialysis probe; 15 min) inhibited evoked responses and background activity in arthritis (n = 9) but had no effect under normal conditions before arthritis (n = 9). "
5.	Chronic Pain 10/16/2019 - "By contrast, NBI27914, a CRF type 1 receptor antagonist, decreased the frequency of sIPSCs in VTA-projecting dlBNST neurons in the chronic pain rats, but not in the control animals. " 10/16/2019 - "Finally, bilateral injections of NBI27914 into the dlBNST of chronic pain rats activated mesolimbic dopaminergic neurons and induced conditioned place preference. " 01/01/2020 - "This may be why intra-dlBNST injections of NPY into chronic pain rats did not exhibit a rewarding effect in the CPP test, whereas intra-dlBNST injections of NBI27914 did. " 01/01/2020 - "Specifically, bilateral intra-dlBNST injections of the CRF type 1 receptor antagonist NBI27914 increased intra-nucleus accumbens dopamine release and induced reward-related behaviors in rats with chronic pain. "

Related Drugs and Biologics

1.	CP 154526
2.	CRF receptor type 1
3.	Urocortins
4.	Ghrelin
5.	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
6.	Cytochromes c (Cytochrome c)
7.	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)
8.	Messenger RNA (mRNA)
9.	Peroxidase (Myeloperoxidase)
10.	Evans Blue (Blue, Evans)

Related Therapies and Procedures

1.	Injections